FDA delays AstraZeneca breast cancer pill decision
#AstraZeneca #CancerResearchAstraZeneca's breast cancer pill camizestrant faces FDA delay for more data after advisory panel voted against its use with a CDK4/6 inhibitor. The company submitted longer-term efficacy results to support approval. read more
There are no other AstraZeneca articles to read at this time.
Check out some of these other topics...